The experimental treatment is based on a technique known as cellular reprogramming, which aims to reverse some of the biological changes associated with aging at the cellular level.
Researchers use a set of genetic factors known as Yamanaka factors to influence the epigenetic system of cells. These factors are intended to partially reset cellular characteristics associated with aging, allowing cells to function more like younger versions of themselves.
According to the company, the therapy includes built-in safety controls designed to regulate gene activity and reduce potential risks during treatment.
Initial Focus on Eye Diseases
The first stage of the research is focused on eye disorders, including glaucoma and other vision-related conditions. Scientists believe the approach may help restore the function of damaged retinal cells and improve their ability to perform essential biological processes.
The trial is currently evaluating whether the therapy can be delivered safely and whether it shows early signs of effectiveness in human patients.
Research Remains in Early Stages
Experts caution that the study remains in its initial phase, and its primary objective is to assess safety rather than demonstrate long-term anti-aging benefits.
While it is too early to determine whether the therapy can meaningfully slow or reverse the aging process, researchers say positive results from future trials could open new avenues for treating age-related diseases and extending healthy lifespan.
If subsequent studies confirm its safety and effectiveness, the technology could represent an important step forward in regenerative medicine and longevity research.
Also Read: Federal government moves to promote herbal medicine sector in Pakistan
Today's E-Paper